Skip to main content
SpringerLink
Log in

Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits

  • Original Articles
  • Daunorubicin Cardiotoxicity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The long-term protective effect of ICRF-187 against chronic daunorubicin cardiotoxicity was examined. Rabbits were given 3.2 mg daunorubicin/kg, with or without pretreatment with 25 mg ICRF-187/kg, once every 3 weeks over an 18-week period (6 doses). The experiment was terminated 3 months after the last treatment. At this time, all seven rabbits given daunorubicin alone had evidence of myocardial alterations ranging from minimal (2 animals) to mild (5 animals). Pretreatment with ICRF-187 caused a significant reduction in both the incidence and the severity of cardiac lesions. Hearts from the majority (5 of 7) of animals given the combination of ICRF-187 and daunorubicin were normal; myocardial alterations were minimal in the remaining rabbits treated with ICRF-187. In previous studies ICRF-187 was found to cause a reduction in cardiotoxicity 1–3 weeks after the final anthracycline dose. The results of the present study demonstrate that pretreatment with ICRF-187 provides prolonged protection against the cardiomyopathy, as opposed to producing only a delay in the appearance of cardiac alterations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Breed JGS, Zimmerman ANE, Dormans JAMA, Pinedo HM (1980) Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res 40:2033

    Google Scholar 

  2. Bristow MR, Billingham ME, Mason JW, Daniels TR (1978) Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873

    Google Scholar 

  3. El-Hage A, Herman EH, Ferrans VJ (1981) Reduction in the diabetic effect of alloxan in mice by pretreatment with the antineoplastic agent ICRF-187. Res Commun Chem Pathol Pharmacol 23:509

    Google Scholar 

  4. Ferrans VJ (1978) Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62:955

    Google Scholar 

  5. Friedman MJ, Ewy GA, Jones SE, Cruze D, Moon TE (1979) 1-year followup of cardiac status after adriamycin therapy. Cancer Treat Rep 63:1809

    Google Scholar 

  6. Gottdiener JS, Mathiser DJ, Borer JS, Bonow RO, Myers CE, Barr LH, Schwartz DE, Bachrach SL, Green ML, Rosenberg SP (1981) Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94:430

    Google Scholar 

  7. Herman EH, Ferrans VJ (1981) Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res 41:3436

    Google Scholar 

  8. Herman EH, Ferrans VJ (1983) Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest 49:69

    Google Scholar 

  9. Herman E, Ardalan B, Bier C, Warakdevar V (1979) Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat Rep 63:89

    Google Scholar 

  10. Herman EH, Ferrans VJ, Jordan W, Ardalen B (1981) Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 31:85

    Google Scholar 

  11. Jaenke RS (1974) An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest 30:292

    Google Scholar 

  12. Jaenke RS (1976) Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res 36: 2958

    Google Scholar 

  13. Legha SS, Wang Y-M, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, Ali MK (1982) Clinical and pharmacologic investigation of the effects of α-tocopherol on adriamycin cardiotoxicity. Ann NY Acad Sci 393:411

    Google Scholar 

  14. Long HJ, Diamond SS, Raflo CP, Burningham RA (1984) Dose-response relationships of chronic adriamycin toxicity in rabbits. Eur J Cancer Clin Oncol 20:129

    Google Scholar 

  15. Mimnaugh EG, Siddik ZH, Drew R, Rikic BI, Gram TE (1979) The effects of α-tocopherol on the toxicity, disposition and metabolism of adriamycin in mice. Toxicol Appl Pharmacol 49:115

    Google Scholar 

  16. Moral R, Bourat C, Ducrot R, Fournal J, Ganter P, Julow L, Kornig F, Myon J, Pascal S, Pasquet J, Populaire P, de Ratuld Y, Werner GH (1976) Etude toxicologique et activité antitumorale expérimentale de la rubidomycine (13-057RP). Pathol Biol Semaine Hop 15:903

    Google Scholar 

  17. Myers CE, McGuire WP, Young R (1976) Adriamycin: Amelioration of toxicity by α-tocopherol. Cancer Treat Rep 60:501

    Google Scholar 

  18. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC (1977) Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165

    Google Scholar 

  19. Myers CE, Gianni L, Simore CB, Klecker R, Greene R (1983) Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 21:1707

    Google Scholar 

  20. Saltiel E (1978) Doxorubicin (adriamycin) cardiomyopathy. West J Med 139:332

    Google Scholar 

  21. Sonneveld P (1978) Effect of α-tocopherol on the cardiotoxicity of adriamycin in the rat. Cancer Treat Rep 62:1033

    Google Scholar 

  22. Tan C, Tasaka H, Yu KP, Murphy ML, Karnovsky DM (1970) Daunomycin, an antitumor antibiotic in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20:333

    Google Scholar 

  23. Van Vleet JF, Ferrans VJ (1980) Clinical and pathologic features of chronic adriamycin toxicosis in the rabbit. Am J Vet Res 41:1462

    Google Scholar 

  24. Von Hoff DD, Layard MW (1982) Risk factors for the development of daunorubicin cardiotoxicity. Cancer Treat Rep 65 [Suppl 4]:15

    Google Scholar 

  25. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rosencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710

    Google Scholar 

  26. Wang Y-M, Madanot FF, Kimball JC, Gleiser CA, Ali MK, Kaufman MW, Van Eys J (1980) Effect of vitamin E against adriamycin toxicity in rabbits. Cancer Res 40:1022

    Google Scholar 

  27. Young DM (1975) Pathologic effects of adriamycin (NSC 123127) in experimental systems. Cancer Chemother Rep 6 (2):159

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Drug Biology, Food and Drug Administration, 20204, Washington, DC, USA

    Eugene H. Herman & Victor J. Ferrans

  2. Pathology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 20205, Bethesda, MD, USA

    Eugene H. Herman & Victor J. Ferrans

Authors
  1. Eugene H. Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor J. Ferrans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herman, E.H., Ferrans, V.J. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother. Pharmacol. 16, 102–106 (1986). https://doi.org/10.1007/BF00256157

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00256157

Keywords

Search

Navigation